|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
|
GB1478759A
(en)
|
1974-11-18 |
1977-07-06 |
Alza Corp |
Process for forming outlet passageways in pills using a laser
|
|
US4284444A
(en)
|
1977-08-01 |
1981-08-18 |
Herculite Protective Fabrics Corporation |
Activated polymer materials and process for making same
|
|
US4200098A
(en)
|
1978-10-23 |
1980-04-29 |
Alza Corporation |
Osmotic system with distribution zone for dispensing beneficial agent
|
|
US4200984A
(en)
|
1979-03-12 |
1980-05-06 |
Fink Ray D |
Detachable tool combining bracket and method
|
|
US4342832A
(en)
|
1979-07-05 |
1982-08-03 |
Genentech, Inc. |
Method of constructing a replicable cloning vehicle having quasi-synthetic genes
|
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
|
ZA811368B
(en)
|
1980-03-24 |
1982-04-28 |
Genentech Inc |
Bacterial polypedtide expression employing tryptophan promoter-operator
|
|
US4398908A
(en)
|
1980-11-28 |
1983-08-16 |
Siposs George G |
Insulin delivery system
|
|
US4456591A
(en)
|
1981-06-25 |
1984-06-26 |
Baxter Travenol Laboratories, Inc. |
Therapeutic method for activating factor VII
|
|
US4435173A
(en)
|
1982-03-05 |
1984-03-06 |
Delta Medical Industries |
Variable rate syringe pump for insulin delivery
|
|
US4542025A
(en)
|
1982-07-29 |
1985-09-17 |
The Stolle Research And Development Corporation |
Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
|
|
US4599311A
(en)
|
1982-08-13 |
1986-07-08 |
Kawasaki Glenn H |
Glycolytic promotersfor regulated protein expression: protease inhibitor
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4870008A
(en)
|
1983-08-12 |
1989-09-26 |
Chiron Corporation |
Secretory expression in eukaryotes
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US5004804A
(en)
|
1984-01-12 |
1991-04-02 |
Nordisk Gentofte |
Method and composition for preparation of factor VIIIC
|
|
US7138505B1
(en)
|
1984-01-12 |
2006-11-21 |
Novartis Vaccines And Diagnostics, Inc. |
Factor VIII:C nucleic acid molecules
|
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US5231112A
(en)
|
1984-04-12 |
1993-07-27 |
The Liposome Company, Inc. |
Compositions containing tris salt of cholesterol hemisuccinate and antifungal
|
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4931373A
(en)
|
1984-05-25 |
1990-06-05 |
Zymogenetics, Inc. |
Stable DNA constructs for expression of α-1 antitrypsin
|
|
AU576889B2
(en)
|
1984-07-24 |
1988-09-08 |
Key Pharmaceuticals, Inc. |
Adhesive transdermal dosage layer
|
|
US4766073A
(en)
|
1985-02-25 |
1988-08-23 |
Zymogenetics Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
|
US4885249A
(en)
|
1984-12-05 |
1989-12-05 |
Allelix, Inc. |
Aspergillus niger transformation system
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
MX9203440A
(en)
|
1985-04-12 |
1992-07-01 |
Genetics Inst |
NOVEL PROCOAGULANT PROTEINS.
|
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
|
ATE74164T1
(en)
|
1985-04-22 |
1992-04-15 |
Genetics Inst |
MANUFACTURING WITH HIGH PERFORMANCE OF ACTIVE FACTOR IX.
|
|
US4684479A
(en)
|
1985-08-14 |
1987-08-04 |
Arrigo Joseph S D |
Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
|
|
KR910006424B1
(en)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
Method of manufacturing knitted briefs
|
|
US4882279A
(en)
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
|
US5198349A
(en)
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
|
US5250421A
(en)
|
1986-01-03 |
1993-10-05 |
Genetics Institute, Inc. |
Method for producing factor VIII:C-type proteins
|
|
WO1987004187A1
(en)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
|
|
US4935349A
(en)
|
1986-01-17 |
1990-06-19 |
Zymogenetics, Inc. |
Expression of higher eucaryotic genes in aspergillus
|
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
DK122686D0
(en)
|
1986-03-17 |
1986-03-17 |
Novo Industri As |
PREPARATION OF PROTEINS
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
US6759057B1
(en)
|
1986-06-12 |
2004-07-06 |
The Liposome Company, Inc. |
Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
|
|
US5610278A
(en)
|
1986-06-24 |
1997-03-11 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
|
IE60901B1
(en)
|
1986-08-21 |
1994-08-24 |
Vestar Inc |
Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
|
|
US4933185A
(en)
|
1986-09-24 |
1990-06-12 |
Massachusetts Institute Of Technology |
System for controlled release of biologically active compounds
|
|
US6024983A
(en)
|
1986-10-24 |
2000-02-15 |
Southern Research Institute |
Composition for delivering bioactive agents for immune response and its preparation
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
US6406713B1
(en)
|
1987-03-05 |
2002-06-18 |
The Liposome Company, Inc. |
Methods of preparing low-toxicity drug-lipid complexes
|
|
US4775207A
(en)
|
1987-03-17 |
1988-10-04 |
Bell Communications Research, Inc. |
Electro-optical switch
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
CA1331157C
(en)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
IL86693A
(en)
|
1987-06-12 |
1994-06-24 |
Stichting Centraal Lab |
Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
|
|
DE3720246A1
(en)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
US4976696A
(en)
|
1987-08-10 |
1990-12-11 |
Becton, Dickinson And Company |
Syringe pump and the like for delivering medication
|
|
FR2619314B1
(en)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
|
|
US4861800A
(en)
|
1987-08-18 |
1989-08-29 |
Buyske Donald A |
Method for administering the drug deprenyl so as to minimize the danger of side effects
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
AU598958B2
(en)
|
1987-11-12 |
1990-07-05 |
Vestar, Inc. |
Improved amphotericin b liposome preparation
|
|
US5270176A
(en)
|
1987-11-20 |
1993-12-14 |
Hoechst Aktiengesellschaft |
Method for the selective cleavage of fusion proteins with lysostaphin
|
|
GB8807504D0
(en)
|
1988-03-29 |
1988-05-05 |
Sandoz Ltd |
Improvements in/relating to organic compounds
|
|
US5037743A
(en)
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
|
JP2717808B2
(en)
|
1988-08-10 |
1998-02-25 |
テルモ株式会社 |
Syringe pump
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
|
WO1990006952A1
(en)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
CA2053864C
(en)
|
1989-02-21 |
2001-11-20 |
Irving Boime |
Modified forms of reproductive hormones
|
|
US5017378A
(en)
|
1989-05-01 |
1991-05-21 |
The University Of Virginia Alumni Patents Foundation |
Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
|
|
AU5741590A
(en)
|
1989-05-04 |
1990-11-29 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
|
US5599907A
(en)
|
1989-05-10 |
1997-02-04 |
Somatogen, Inc. |
Production and use of multimeric hemoglobins
|
|
US5298022A
(en)
|
1989-05-29 |
1994-03-29 |
Amplifon Spa |
Wearable artificial pancreas
|
|
FR2647677B1
(en)
|
1989-05-31 |
1991-09-27 |
Roussel Uclaf |
NOVEL MICRO-PROTEINS, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW MICRO-PROTEINS
|
|
US7413537B2
(en)
|
1989-09-01 |
2008-08-19 |
Dyax Corp. |
Directed evolution of disulfide-bonded micro-proteins
|
|
SE465222C5
(en)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
A recombinant human factor VIII derivative and process for its preparation
|
|
US5492534A
(en)
|
1990-04-02 |
1996-02-20 |
Pharmetrix Corporation |
Controlled release portable pump
|
|
US5318540A
(en)
|
1990-04-02 |
1994-06-07 |
Pharmetrix Corporation |
Controlled release infusion device
|
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
|
US5176502A
(en)
|
1990-04-25 |
1993-01-05 |
Becton, Dickinson And Company |
Syringe pump and the like for delivering medication
|
|
US6517859B1
(en)
|
1990-05-16 |
2003-02-11 |
Southern Research Institute |
Microcapsules for administration of neuroactive agents
|
|
US5215680A
(en)
|
1990-07-10 |
1993-06-01 |
Cavitation-Control Technology, Inc. |
Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
|
|
US5583107A
(en)
|
1990-09-04 |
1996-12-10 |
Cor Therapeutics, Inc. |
Agents affecting thrombosis and hemostasis
|
|
WO1992010576A1
(en)
|
1990-12-13 |
1992-06-25 |
The Upjohn Company |
Fusion polypeptides
|
|
US5206161A
(en)
|
1991-02-01 |
1993-04-27 |
Genentech, Inc. |
Human plasma carboxypeptidase B
|
|
US20060122376A1
(en)
|
1991-02-07 |
2006-06-08 |
Chiron Corporation |
Protein complexes having factor VIII:C activity and production thereof
|
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
|
DK0575545T3
(en)
|
1991-03-15 |
2003-09-15 |
Amgen Inc |
Pegylation of polypeptides
|
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
US5859204A
(en)
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
|
US6376463B1
(en)
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
|
ATE198277T1
(en)
|
1992-10-02 |
2001-01-15 |
Genetics Inst |
COMPOSITION INCLUDING COAGULATION FACTOR VIII; METHOD FOR THE PRODUCTION THEREOF AND THE USE OF A SURFACE-ACTIVE SUBSTANCE AS A STABILIZER
|
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
|
US5573776A
(en)
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
|
US5554730A
(en)
|
1993-03-09 |
1996-09-10 |
Middlesex Sciences, Inc. |
Method and kit for making a polysaccharide-protein conjugate
|
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
DK0809110T3
(en)
|
1993-03-09 |
2004-05-24 |
Baxter Int |
Macromolecular microparticles and methods of preparation
|
|
SE504074C2
(en)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Protein preparation for subcutaneous, intramuscular or intradermal administration
|
|
US5576291A
(en)
|
1993-09-13 |
1996-11-19 |
Baxter International Inc. |
Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US20020042079A1
(en)
|
1994-02-01 |
2002-04-11 |
Sanford M. Simon |
Methods and agents for measuring and controlling multidrug resistance
|
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
SE503424C2
(en)
|
1994-11-14 |
1996-06-10 |
Pharmacia Ab |
Process for purification of recombinant coagulation factor VIII
|
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US7846455B2
(en)
|
1996-07-15 |
2010-12-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Attenuated chimeric respiratory syncytial virus
|
|
SE9503380D0
(en)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
EP1683520B1
(en)
|
1996-03-12 |
2013-11-20 |
PG-TXL Company, L.P. |
Water-soluble prodrugs
|
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
|
US8183344B2
(en)
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
US7560107B2
(en)
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
PT929293E
(en)
|
1996-08-23 |
2004-03-31 |
Sequus Pharm Inc |
LIPOSOMES CONTAINING A COMPOSITE OF CISPLATIN
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
EP0932390A1
(en)
|
1996-10-11 |
1999-08-04 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method
|
|
HUP0000522A3
(en)
|
1996-10-15 |
2000-10-30 |
Transave Inc Monmouth Junction |
N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
|
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
|
US6110498A
(en)
|
1996-10-25 |
2000-08-29 |
Shire Laboratories, Inc. |
Osmotic drug delivery system
|
|
AU5065198A
(en)
|
1996-11-15 |
1998-06-10 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
EP0842657A1
(en)
|
1996-11-19 |
1998-05-20 |
OctoPlus B.V. |
Microspheres for controlled release and processes to prepare these microspheres
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
AT405516B
(en)
|
1997-02-27 |
1999-09-27 |
Immuno Ag |
FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
|
GB2339430A
(en)
|
1997-05-21 |
2000-01-26 |
Biovation Ltd |
Method for the production of non-immunogenic proteins
|
|
US7786070B2
(en)
|
1997-09-10 |
2010-08-31 |
Novo Nordisk Healthcare A/G |
Subcutaneous administration of coagulation factor VII
|
|
US6310183B1
(en)
|
1997-09-10 |
2001-10-30 |
Novo Nordisk A/S |
Coagulation factor VIIa composition
|
|
DE19747261A1
(en)
|
1997-10-25 |
1999-04-29 |
Bayer Ag |
Single-chamber osmotic pharmaceutical release system
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
ES2255155T3
(en)
|
1998-02-05 |
2006-06-16 |
Biosense Webster, Inc. |
DEVICE FOR THE INTRACARDIAC ADMINISTRATION OF PHARMACOS.
|
|
AU3289199A
(en)
|
1998-02-11 |
1999-08-30 |
Maxygen, Inc. |
Antigen library immunization
|
|
US20050260605A1
(en)
|
1998-02-11 |
2005-11-24 |
Maxygen, Inc. |
Targeting of genetic vaccine vectors
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(en)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
|
|
US6406632B1
(en)
|
1998-04-03 |
2002-06-18 |
Symyx Technologies, Inc. |
Rapid characterization of polymers
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US7090976B2
(en)
|
1999-11-10 |
2006-08-15 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions comprising Renilla GFP
|
|
GB9815157D0
(en)
|
1998-07-13 |
1998-09-09 |
Metron Designs Ltd |
High resolution pulse width setting from relatively low frequency clocks
|
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US20030190740A1
(en)
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
|
EP1129186B2
(en)
|
1998-11-10 |
2016-11-30 |
Stichting Sanquin Bloedvoorziening |
A factor viii-polypeptide with factor viii:c-activity
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6329186B1
(en)
|
1998-12-07 |
2001-12-11 |
Novozymes A/S |
Glucoamylases with N-terminal extensions
|
|
US6358703B1
(en)
*
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
|
US6713086B2
(en)
|
1998-12-18 |
2004-03-30 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR20060067983A
(en)
|
1999-01-15 |
2006-06-20 |
제넨테크, 인크. |
Polypeptide variants with altered effector function
|
|
DK1161274T3
(en)
|
1999-03-03 |
2005-05-09 |
Optinose As |
Nasal administration device
|
|
US6183770B1
(en)
|
1999-04-15 |
2001-02-06 |
Acutek International |
Carrier patch for the delivery of agents to the skin
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US6743211B1
(en)
|
1999-11-23 |
2004-06-01 |
Georgia Tech Research Corporation |
Devices and methods for enhanced microneedle penetration of biological barriers
|
|
US7829085B2
(en)
|
1999-07-14 |
2010-11-09 |
Life Sciences Research Partners Vzw |
Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
|
|
ATE279437T1
(en)
|
1999-08-06 |
2004-10-15 |
Genentech Inc |
PEPTIDE ANTAGONISTS OF FACTOR VIIA
|
|
US6458387B1
(en)
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
|
US20030109428A1
(en)
|
1999-12-01 |
2003-06-12 |
John Bertin |
Novel molecules of the card-related protein family and uses thereof
|
|
US20050287153A1
(en)
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
US6352721B1
(en)
|
2000-01-14 |
2002-03-05 |
Osmotica Corp. |
Combined diffusion/osmotic pumping drug delivery system
|
|
ATE428445T1
(en)
|
2000-02-11 |
2009-05-15 |
Bayer Healthcare Llc |
CLOTTING FACTOR VII OR VIIA CONJUGATES
|
|
DK1252192T3
(en)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Enhancement of the serum half-life of antibody-based fusion proteins
|
|
EP1803730A1
(en)
|
2000-04-12 |
2007-07-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US6962972B2
(en)
|
2000-05-16 |
2005-11-08 |
Lipoxen Technologies Limited |
Derivatization of proteins
|
|
DE60140625D1
(en)
|
2000-08-15 |
2010-01-07 |
Univ Illinois |
PROCESS FOR PRODUCING MICROPARTICLES
|
|
US7176288B2
(en)
|
2000-09-13 |
2007-02-13 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
|
AU2001292861A1
(en)
|
2000-09-19 |
2002-04-02 |
Emory University |
Modified factor VIII
|
|
DE10053224A1
(en)
|
2000-10-26 |
2002-05-08 |
Univ Goettingen Georg August |
Procedure for the exposure of peptides and polypeptides to the cell surface of bacteria
|
|
US20030228309A1
(en)
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
DK1355919T3
(en)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molecules with longer half-lives, compositions and uses thereof
|
|
US20030104591A1
(en)
|
2000-12-14 |
2003-06-05 |
Murray Christopher J. |
Methods and compositions for grafting functional loops into a protein
|
|
US20030049689A1
(en)
|
2000-12-14 |
2003-03-13 |
Cynthia Edwards |
Multifunctional polypeptides
|
|
CA2433439A1
(en)
|
2000-12-29 |
2002-08-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
IN190699B
(en)
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
|
WO2002062377A2
(en)
|
2001-02-05 |
2002-08-15 |
Novo Nordisk Health Care Ag |
Combined use of factor vii polypeptides and factor viii polypeptides
|
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
|
AU2002335930B2
(en)
|
2001-03-09 |
2005-07-28 |
Morphosys Ag |
Serum albumin binding moieties
|
|
US20020169125A1
(en)
|
2001-03-21 |
2002-11-14 |
Cell Therapeutics, Inc. |
Recombinant production of polyanionic polymers and uses thereof
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
EP1397160A1
(en)
|
2001-04-30 |
2004-03-17 |
Shire Laboratories Inc. |
Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
|
|
US6838093B2
(en)
|
2001-06-01 |
2005-01-04 |
Shire Laboratories, Inc. |
System for osmotic delivery of pharmaceutically active agents
|
|
US20040192599A1
(en)
|
2001-06-15 |
2004-09-30 |
Schuh Andre C |
Gene therapy for hemophilia a
|
|
KR100407467B1
(en)
|
2001-07-12 |
2003-11-28 |
최수봉 |
Insulin pump operated by remote-controller
|
|
WO2003011213A2
(en)
|
2001-07-30 |
2003-02-13 |
Eli Lilly And Company |
Method for treating diabetes and obesity
|
|
SG177002A1
(en)
|
2001-10-10 |
2012-01-30 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
|
CA2469477A1
(en)
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
KR101271635B1
(en)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Albumin fusion proteins
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US20080167238A1
(en)
|
2001-12-21 |
2008-07-10 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
JP2006502091A
(en)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
Bispecific antibody point mutations to increase clearance rate
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
ATE488581T1
(en)
|
2002-04-30 |
2010-12-15 |
Bayer Healthcare Llc |
FACTOR VII OR FACTOR VIIA POLYPEPTIDE VARIANTS
|
|
US6945952B2
(en)
|
2002-06-25 |
2005-09-20 |
Theraject, Inc. |
Solid solution perforator for drug delivery and other applications
|
|
US7294513B2
(en)
|
2002-07-24 |
2007-11-13 |
Wyatt Technology Corporation |
Method and apparatus for characterizing solutions of small particles
|
|
PT1534335E
(en)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004027901A2
(en)
|
2002-09-17 |
2004-04-01 |
Diffusion Science, Inc. |
Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres
|
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
|
EP3502133A1
(en)
|
2002-09-27 |
2019-06-26 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
PT1562972E
(en)
|
2002-10-15 |
2010-11-10 |
Facet Biotech Corp |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
PT1596887T
(en)
|
2003-02-26 |
2022-04-14 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
|
KR100851263B1
(en)
|
2003-02-28 |
2008-08-08 |
가부시키가이샤 구라레 |
Curable resin composition
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20050176108A1
(en)
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
SI2077121T1
(en)
|
2003-05-06 |
2011-07-29 |
Syntonix Pharmaceuticals Inc |
Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder
|
|
US7132398B2
(en)
|
2003-05-06 |
2006-11-07 |
Dendreon Corporation |
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
|
|
US20070161087A1
(en)
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
|
CA2526120A1
(en)
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
|
KR101113726B1
(en)
|
2003-08-12 |
2012-02-27 |
리폭센 테크놀로지즈 리미티드 |
Sialic acid derivatives for protein derivatisation and conjugation
|
|
AU2004264265C1
(en)
|
2003-08-14 |
2012-06-28 |
Thrombogenics Nv |
Antibodies against factor VIII with modified glycosylation in the variable region
|
|
US20050152979A1
(en)
|
2003-09-05 |
2005-07-14 |
Cell Therapeutics, Inc. |
Hydrophobic drug compositions containing reconstitution enhancer
|
|
CN1863908B
(en)
|
2003-09-09 |
2010-08-04 |
诺和诺德医疗保健公司 |
Coagulation factor vii polypeptides
|
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1682106A4
(en)
|
2003-10-30 |
2008-06-11 |
Univ Emory |
Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
US20080193441A1
(en)
|
2003-11-18 |
2008-08-14 |
Iconic Therapeutics, Inc. |
Homogeneous Preparations of Chimeric Protein
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
US20060148680A1
(en)
|
2004-01-14 |
2006-07-06 |
Kieliszewski Marcia J |
Glycoproteins produced in plants and methods of their use
|
|
ES2567634T3
(en)
|
2004-02-09 |
2016-04-25 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US20080233100A1
(en)
|
2004-06-30 |
2008-09-25 |
Yiyou Chen |
Targeted enzymes
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
EP1797127B1
(en)
|
2004-09-24 |
2017-06-14 |
Amgen Inc. |
Modified fc molecules
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
UA95225C2
(en)
|
2004-11-12 |
2011-07-25 |
Байер Хелскер Ллс |
Modified with polymer factor viii for the treatment of haemophilia and process for the preparation thereof
|
|
PL1835938T3
(en)
|
2004-12-27 |
2014-01-31 |
Baxalta Inc |
Polymer-von willebrand factor-conjugates
|
|
CA2595695A1
(en)
|
2005-01-25 |
2006-08-03 |
Cell Therapeutics, Inc. |
Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
EP1871801A2
(en)
|
2005-04-01 |
2008-01-02 |
Novo Nordisk Health Care AG |
Blood coagulation fviii analogues
|
|
CA2604299A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
JP2009504157A
(en)
|
2005-08-12 |
2009-02-05 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
Albumin fusion protein
|
|
JP2009508510A
(en)
|
2005-09-21 |
2009-03-05 |
ノボ ノルディスク ヘルス ケア アーゲー |
Human coagulation factor VII polypeptide
|
|
US20090099031A1
(en)
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
AU2006294644A1
(en)
|
2005-09-27 |
2007-04-05 |
Amunix, Inc. |
Proteinaceous pharmaceuticals and uses thereof
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
EP1971355B1
(en)
|
2005-12-20 |
2020-03-11 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
FR2897868B1
(en)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
ANTI-IDIOTYPIC ANTIBODIES THAT NEUTRALIZE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST FIELD C1 OF FACTOR VIII.
|
|
EP1996937A4
(en)
|
2006-03-06 |
2009-04-08 |
Amunix Inc |
Genetic packages and uses thereof
|
|
CA2643182C
(en)
|
2006-03-13 |
2014-09-02 |
Tir Technology Lp |
Adaptive control apparatus and method for a solid-state lighting system
|
|
US7683158B2
(en)
|
2006-03-31 |
2010-03-23 |
Baxter International Inc. |
Pegylated factor VIII
|
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
|
US20090169553A1
(en)
|
2006-05-04 |
2009-07-02 |
Molecular Innovations |
Novel Protein Fusion/Tag Technology
|
|
EP2032607B2
(en)
|
2006-06-14 |
2017-02-22 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
|
EP1867660A1
(en)
|
2006-06-14 |
2007-12-19 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
EP2049144B8
(en)
|
2006-07-21 |
2015-02-18 |
ratiopharm GmbH |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
JP5290177B2
(en)
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
|
MX2009002816A
(en)
|
2006-09-14 |
2009-05-28 |
Human Genome Sciences Inc |
Albumin fusion proteins.
|
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
BRPI0717505B8
(en)
|
2006-10-04 |
2021-05-25 |
Novo Nordisk As |
peptide conjugate and pharmaceutical formulation
|
|
WO2008049711A1
(en)
|
2006-10-27 |
2008-05-02 |
Novo Nordisk A/S |
Peptide extended insulins
|
|
CN101190945A
(en)
|
2006-11-29 |
2008-06-04 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
Preparation for specificity anticoagulant substance and application thereof
|
|
EP1935430A1
(en)
|
2006-12-22 |
2008-06-25 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
|
WO2008077616A1
(en)
|
2006-12-22 |
2008-07-03 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
CA2671676C
(en)
|
2006-12-27 |
2014-04-22 |
Baxter Healthcare Sa |
Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
|
|
WO2008081024A1
(en)
|
2007-01-03 |
2008-07-10 |
Novo Nordisk Health Care Ag |
Subcutaneous administration of coagulation factor viia-related popypeptdes
|
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
|
EP2108045B1
(en)
|
2007-02-01 |
2013-12-11 |
Baxter International Inc. |
Improved fix-mutant proteins for hemophilia b treatment
|
|
EP2517714A1
(en)
|
2007-04-26 |
2012-10-31 |
Inspiration Biopharmaceuticals, Inc. |
Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
|
|
ES2362386T3
(en)
|
2007-06-21 |
2011-07-04 |
Technische Universität München |
ACTIVE BIOLOGICAL PROTEINS THAT HAVE INCREASED STABILITY IN VIVO AND / OR IN VITRO.
|
|
AU2008287340A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
CN101965409A
(en)
|
2007-11-01 |
2011-02-02 |
罗切斯特大学 |
Recombinant factor VIII with stability of increase
|
|
WO2009062100A1
(en)
|
2007-11-09 |
2009-05-14 |
Baxter International Inc. |
Modified recombinant factor viii and von willebrand factor and methods of use
|
|
BRPI0821474B8
(en)
|
2007-12-28 |
2021-05-25 |
Baxalta GmbH |
stable liquid pharmaceutical formulation
|
|
JP5444629B2
(en)
|
2008-04-03 |
2014-03-19 |
富士通株式会社 |
Light guide mechanism for illuminance sensor and mobile phone
|
|
AR071478A1
(en)
|
2008-04-17 |
2010-06-23 |
Baxter Healthcare Sa |
PEPTIDES OF LOW MOLECULAR WEIGHT WITH PROCOAGULANT ACTIVITY FOR THE TREATMENT OF PATIENTS WITH FACTOR DEFICIENCY V (FV), FVII, FVIII, FX AND / OR FXI
|
|
CN102112623A
(en)
|
2008-06-04 |
2011-06-29 |
拜耳医药保健有限公司 |
FVIII muteins for treatment of von willebrand disease
|
|
AU2009262476C1
(en)
*
|
2008-06-24 |
2016-06-02 |
Csl Behring Gmbh |
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
|
|
KR20110093775A
(en)
|
2008-11-03 |
2011-08-18 |
바이엘 헬스케어 엘엘씨 |
Method for the treatment of hemophilia
|
|
WO2010060081A1
(en)
|
2008-11-24 |
2010-05-27 |
Bayer Healthcare Llc |
Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
|
|
NZ593833A
(en)
*
|
2009-02-03 |
2013-10-25 |
Amunix Operating Inc |
Extended recombinant polypeptides and compositions comprising same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
JP5739865B2
(en)
|
2009-03-24 |
2015-06-24 |
バイエル・ヘルスケア・エルエルシー |
Factor VIII variants and methods of use
|
|
DE202010018378U1
(en)
|
2009-04-10 |
2016-04-07 |
Tufts Medical Center, Inc. |
PAR-1 activation by metalloproteinase-1 (MMP-1)
|
|
BRPI1010880A2
(en)
|
2009-06-08 |
2019-10-01 |
Amunix Operating Inc |
growth hormone polypeptides and methods of making and using them.
|
|
PT2440228T
(en)
|
2009-06-08 |
2018-12-24 |
Amunix Operating Inc |
Glucose-regulating polypeptides and methods of making and using same
|
|
EP2467166A2
(en)
|
2009-08-20 |
2012-06-27 |
CSL Behring GmbH |
Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
|
|
JP2013502458A
(en)
|
2009-08-24 |
2013-01-24 |
アムニクス オペレーティング インコーポレイテッド |
Coagulation factor VII composition and methods of making and using the same
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
JP5876416B2
(en)
|
2009-11-13 |
2016-03-02 |
グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Von Willebrand factor (vWF) containing preparations and related methods, kits and uses
|
|
MX336830B
(en)
|
2009-12-06 |
2016-02-03 |
Biogen Hemophilia Inc |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof.
|
|
WO2011084808A2
(en)
|
2009-12-21 |
2011-07-14 |
Amunix Operating Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
|
US9493543B2
(en)
|
2010-02-16 |
2016-11-15 |
Novo Nordisk A/S |
Factor VIII fusion protein
|
|
JP5914363B2
(en)
|
2010-02-16 |
2016-05-11 |
ノヴォ ノルディスク アー／エス |
Factor VIII molecule with reduced VWF binding
|
|
US8466059B2
(en)
*
|
2010-03-30 |
2013-06-18 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Multi-layer interconnect structure for stacked dies
|
|
WO2011123830A2
(en)
*
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
EP3372617B1
(en)
*
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
US9637789B2
(en)
|
2010-04-21 |
2017-05-02 |
Jan Astermark and Erik Berntorp |
Genetic factors associated with inhibitor development in hemophilia A
|
|
MX2012013381A
(en)
|
2010-05-20 |
2013-02-21 |
Allergan Inc |
Degradable clostridial toxins.
|
|
EP3508573A1
(en)
*
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
|
MX2013000301A
(en)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors.
|
|
SG10201505218YA
(en)
|
2010-07-09 |
2015-08-28 |
Biogen Hemophilia Inc |
Factor ix polypeptides and methods of use thereof
|
|
US20130183280A1
(en)
|
2010-07-15 |
2013-07-18 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
HUE043894T2
(en)
|
2011-06-10 |
2019-09-30 |
Bioverativ Therapeutics Inc |
Pro-coagulant compounds and methods of use thereof
|
|
CN104114454B
(en)
|
2011-12-21 |
2017-02-22 |
恩特格里斯公司 |
Liner-based shipping and dispensing systems
|
|
CN109111526A
(en)
|
2012-01-12 |
2019-01-01 |
比奥贝拉蒂治疗公司 |
Chimeric factor VIII polypeptide and application thereof
|
|
KR102097263B1
(en)
|
2012-02-15 |
2020-04-06 |
바이오버라티브 테라퓨틱스 인크. |
Factor viii compositions and methods of making and using same
|
|
DK2822577T3
(en)
*
|
2012-02-15 |
2019-04-01 |
Bioverativ Therapeutics Inc |
RECOMBINANT FACTOR VIII PROTEINS
|
|
CN104411716B
(en)
|
2012-04-24 |
2018-09-07 |
诺和诺德股份有限公司 |
Compounds suitable for treatment of haemophilia
|
|
US20150045303A1
(en)
|
2012-04-24 |
2015-02-12 |
Novo Nordisk A/S |
Pharmaceutical Composition Suitable for Treatment of Haemophilia
|
|
AU2013290173B2
(en)
|
2012-07-11 |
2018-02-15 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
BR112014032998A2
(en)
|
2012-07-18 |
2017-06-27 |
Univ Northwestern |
method to form ethylene from methane
|
|
WO2014100913A1
(en)
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
|
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
|
TW201536811A
(en)
|
2013-05-31 |
2015-10-01 |
Biogen Idec Inc |
Chimeric FVII-XTEN molecules and uses thereof
|
|
WO2014198699A2
(en)
|
2013-06-12 |
2014-12-18 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
WO2014210547A1
(en)
|
2013-06-28 |
2014-12-31 |
Biogen Idec Ma Inc. |
Thrombin cleavable linker
|
|
KR20240148954A
(en)
|
2013-06-28 |
2024-10-11 |
바이오버라티브 테라퓨틱스 인크. |
Thrombin cleavable linker with xten and its uses thereof
|
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
|
PL4176894T3
(en)
|
2014-01-10 |
2024-07-22 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric proteins and uses thereof
|